This months HIDDEN GEM IS Labopharm Inc. (NasdaqGM: DDSS)
HIDDEN GEM FOR NOVEMBER (DDSS - Labopharm Inc. Price: $1.55) a defensive biotech company with 100%+ potential and limited downside risk due to a recent FDA ruling on 10/07/09. Three research houses raised guidance per FDA ruling 10/08/09.
FDA found no efficacy or safety issues in July letter to DDSS.
http://www.labopharm.com/Default.aspx?id=83&reqId=1309052
http://finance.yahoo.com/news/Labopharm-announces-that-its-prnews-1174529232.html?x=0&.v=57
Sales potential from new drug: 550M
Three Broker upgrades: after FDA approved manufacturing plant.
Labopharm Tgt Raised To C$3 From C$2 By Versant - 10/8/2009
Labopharm Inc. Tgt Raised To C$2.50 From C$1.45 By Dundee - 10/8/2009
Labopharm Tgt Raised To C$2.80 From C$2.60 By Canaccord - 10/08/2009
Key to drug is huge market 19.9B.......DDSS drug has a decided advantage in that no weight gain seen and no sleep problems.
Article link on weight gain problems http://www.webmd.com/depression/features/antidepressants-weight-gain
Stock had bottomed as price started to advance late week as an 8 month trendline held in mid 1.40's. Stock was strong Wednesday, Thursday, and Friday even though major indexs were plunging.
Important Note:
"...One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo...."
http://www.news-medical.net/news/2008/11/24/43336.aspx
http://www.emedexpert.com/facts/trazodone-facts.shtml
http://www.emedexpert.com/compare-meds/trazodone.shtml
http://www.pharmafocus.com/cda/focusH/1,2109,21-0-0-OCT_2009-focus_news_detail-0-493264,00.html
FDA found no efficacy or safety issues in July letter to DDSS.
http://www.labopharm.com/Default.aspx?id=83&reqId=1309052
http://finance.yahoo.com/news/Labopharm-announces-that-its-prnews-1174529232.html?x=0&.v=57
Sales potential from new drug: 550M
Three Broker upgrades: after FDA approved manufacturing plant.
Labopharm Tgt Raised To C$3 From C$2 By Versant - 10/8/2009
Labopharm Inc. Tgt Raised To C$2.50 From C$1.45 By Dundee - 10/8/2009
Labopharm Tgt Raised To C$2.80 From C$2.60 By Canaccord - 10/08/2009
Key to drug is huge market 19.9B.......DDSS drug has a decided advantage in that no weight gain seen and no sleep problems.
Article link on weight gain problems http://www.webmd.com/depression/features/antidepressants-weight-gain
Stock had bottomed as price started to advance late week as an 8 month trendline held in mid 1.40's. Stock was strong Wednesday, Thursday, and Friday even though major indexs were plunging.
Important Note:
"...One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo...."
http://www.news-medical.net/news/2008/11/24/43336.aspx
http://www.emedexpert.com/facts/trazodone-facts.shtml
http://www.emedexpert.com/compare-meds/trazodone.shtml
http://www.pharmafocus.com/cda/focusH/1,2109,21-0-0-OCT_2009-focus_news_detail-0-493264,00.html
6 comments:
here we go with the chest pounding again...he gets a few hundred idiots to buy a stock that trades a couple hundred thousand shares a day....it goes up 10% and we'll never hear the end of it.....wish we'd hear more about NYX @ 170 and the reasoning behind that call!!
he is at least trying. quit bringing up the NYX call..that was 2 years ago...get over it...
Greg pumping this all over the yahoo boards. Makes you wonder what his intentions are, as well as the motives on this site. Is he doing another one of his pump and dumps. I guess we will see.
yep it was 2 years ago and it's still yet to get over 30 bucks, nice call!!
ahh yes, 3 brokerages upgraded DDSS, just the kind of thing I like to stay away from, my only question would be, do they get a trip to Hawaii or or Australia for the pumping?
By reading the company profile on Yahoo I was able to find out this company used to go by the name CRAP, Inc.
NO LIE - http://finance.yahoo.com/q/pr?s=DDSS
Post a Comment